Pediatric neuromodulation device development faces unique barriers such as ethical concerns, small trial populations, and financial disincentives that require targeted FDA initiatives to overcome.
Addressing regulatory and financial barriers through FDA initiatives and alternative pathways could expand access to FDA-approved neuromodulation devices for pediatric patients.
While neuromodulation devices for managing neurological conditions have significantly advanced, there remains a substantial gap in FDA-approved devices specifically designed for pediatric patients. Devices like deep brain stimulators (DBS), vagus nerve stimulators (VNS), and spinal cord stimulators (SCS) are primarily approved for adults, with few options for children. To meet pediatric needs, off-label use is common; however, unique challenges to pediatric device development-such as ethical concerns, small trial populations, and financial disincentives due to the limited market size-continue to hinder progress. This review examines these barriers to pediatric neuromodulation device development and FDA (Food and Drug Administration) approval, as well as the current efforts, such as FDA initiatives and consortia support, that address regulatory and financial challenges. Furthermore, we discuss pathways like the Humanitarian Device Exemptions and Real-World Evidence programs that aim to streamline the approval process and address unmet clinical needs in pediatric care. Addressing these barriers could expand access to effective neuromodulation treatments and improve patient care.
Shaikhouni et al. (Mon,) conducted a review in Neurological conditions in pediatric patients. Pediatric neuromodulation devices was evaluated. Pediatric neuromodulation device development faces unique barriers such as ethical concerns, small trial populations, and financial disincentives that require targeted FDA initiatives to overcome.